David Hough, MD
David Hough, MD is the Chief Medical Officer at Freedom Biosciences. Prior to joining Freedom, Dr. Hough spent 17 years in various leadership roles at Janssen Research and Development, LLC (a Johnson & Johnson company). Most recently, he was the leader of the compound development team working on Spravato (esketamine). In this role, Dr. Hough oversaw the program through the development of novel indications for two severe mood disorders, and was responsible for all the medical, scientific, manufacturing, quality, preclinical, and commercial aspects of the program.
Alex Kwan, PhD
Alex Kwan is a neuroscientist whose work is focused on the neurobiology of antidepressants. He is known for using sophisticated optical imaging methods to show how drugs such as ketamine and psilocybin modify the structure and function of brain circuitry. His research has been published in top peer-reviewed journals including Nature Neuroscience, Neuron, and Biological Psychiatry. He has a Ph.D. in Applied Physics from Cornell University and is currently an Associate Professor in the Meinig School of Biomedical Engineering at Cornell University.
Gerard Sanacora, MD, PhD
Dr. Gerard Sanacora is the George D. Gross and Esther S. Gross Professor of Psychiatry at the Yale University School of Medicine, Director of the Yale Depression Research Program, and Co-Director of the Interventional Psychiatry Program at Yale-New Haven Hospital. For the past 25 years his research has focused using both preclinical and clinical studies in attempts to expand our understanding of the pathophysiology of mood disorders and to use this information in developing new approaches in treating mood and other neuropsychiatric disorders.
Frank Menniti, PhD
Frank S. Menniti, Ph.D., is a neuropharmacologist with BioPharmaWorks, LLC and a Ryan Research Professor of Neuroscience and Adjunct Professor, Department of Biomedical and Pharmaceutical Sciences, in the College of Pharmacy at the University of Rhode Island. Prior to this, he served as Founder and Chief Science Officer of MindImmune Therapeutics, Inc., a drug discovery company focused on developing immune modulators to treat diseases of the mind and brain. Prior to MindImmune, He was the Founder and Chief Scientific Officer of Mnemosyne Pharmaceuticals, Inc. developing subunit-selective NMDA receptor modulators.